



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The Agami Duniya		
Date	24 th November 2025	Language	English
Headline	IIT Bhubaneswar and ILS Transfer Novel TB Vaccine Technology to TechInvention: Facilitated by NRDC		
Link	https://agamiduniya.in/?p=2590		



Bhubaneswar, 24th November 2025:(A.D.News) Indian Institute of Technology (IIT) Bhubaneswar and the Institute of Life Sciences (ILS), Bhubaneswar, along with the National Research Development Corporation (NRDC), have signed a Quadripartite License Agreement (QLA) with TechInvention Lifecare Limited for the technology transfer and future commercialization of a novel TB vaccine candidate titled “HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium tuberculosis.” Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, claiming 1.23 million lives in 2024 alone, as reported by the WHO. Ending the TB epidemic by 2030 is a key global health priority under the United Nations Sustainable Development Goals (SDGs). However, the world continues to rely on the Bacillus Calmette Guérin (BCG) vaccine, developed over a century ago, which provides only limited protection mainly to infants and is largely ineffective in preventing pulmonary TB in adolescents and adults. To address this critical unmet need, a next-generation HSP Subunit Vaccine has been developed through collaborative research led by Prof. Ashis Biswas of Indian Institute of Technology (IIT) Bhubaneswar and Dr. Sunil Kumar Raghav of Institute of Life Sciences (ILS), Bhubaneswar. This vaccine candidate is designed to trigger strong humoral and cell-mediated immune responses while enhancing the protective efficacy of the existing BCG vaccine. In view of its significant public health potential, National Research Development Corporation (NRDC) proactively identified and evaluated this technology and facilitated the licensing process to ensure its advancement. The technology exchange was held at ILS Bhubaneswar in the presence of several senior dignitaries including Dr. Debasis Dash, Director, ILS; Prof. Shreepad Karmalkar, Director, IIT Bhubaneswar; Prof. Dinakar Pasla, Dean (Sponsored Research & Industrial Consultancy), IIT Bhubaneswar; Dr. B. K. Sahu, Senior Regional Manager & Head Outreach Offices, NRDC; Syed S. Ahmed, Director & CEO, TechInvention



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Lifecare Limited; Dr. Sunil Kumar Raghav, Scientist F, ILS Bhubaneswar; Dr. Ashis Biswas, Professor, School of Basic Sciences, IIT Bhubaneswar, along with other distinguished guests.

The HSP Subunit Vaccine candidate, jointly developed by the premier institutions ILS and IIT Bhubaneswar, represents a significant advancement in India's efforts to combat Mycobacterium tuberculosis. This collaboration reflects the robustness of India's research ecosystem and its commitment to addressing critical public health challenges.

TechInvention Lifecare Limited, the licensed industry partner, will play a key role in translating this indigenous vaccine technology into a viable public health solution. With strong expertise in vaccine development, regulatory readiness, and global health innovation, TechInvention brings deep technical strength and established manufacturing capabilities.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The Statesman		
Date	24 th November 2025	Language	English
Headline	IIT-Bhubaneswar, ILS transfer novel TB vaccine technology to TechInvention		
Link	https://www.thestatesman.com/india/iit-bhubaneswar-ils-transfer-novel-tb-vaccine-technology-to-techinvention-1503516838.html		



Indian Institute of Technology (IIT)-Bhubaneswar and the Institute of Life Sciences (ILS), Bhubaneswar, along with the National Research Development Corporation (NRDC), have signed a Quadripartite License Agreement (QLA) with TechInvention Lifecare Limited for the technology transfer and future commercialization of a novel TB vaccine candidate titled “HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium tuberculosis.”

Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, claiming 1.23 million lives in 2024 alone, as reported by the WHO. Ending the TB epidemic by 2030 is a key global health priority under the United Nations Sustainable Development Goals (SDGs). However, the world continues to rely on the Bacillus Calmette Guérin (BCG) vaccine, developed over a century ago, which provides only limited protection mainly to infants and is largely ineffective in preventing pulmonary TB in adolescents and adults.

To address this critical unmet need, a next-generation HSP Subunit Vaccine has been developed through collaborative research led by Prof. Ashis Biswas of Indian Institute of Technology (IIT) Bhubaneswar and Dr. Sunil Kumar Raghav of Institute of Life Sciences (ILS), Bhubaneswar.

This vaccine candidate is designed to trigger strong humoral and cell-mediated immune responses while enhancing the protective efficacy of the existing BCG vaccine. In view of its significant public health potential, National Research Development Corporation (NRDC) proactively identified and evaluated this technology and facilitated the licensing process to ensure its advancement. The technology exchange was held at ILS Bhubaneswar in the presence of several senior dignitaries including Dr. Debasis Dash, Director, ILS; Prof. Shreepad Karmalkar, Director, IIT Bhubaneswar; Prof. Dinakar Pasla, Dean (Sponsored Research



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

& Industrial Consultancy), IIT Bhubaneswar; Dr. B. K. Sahu, Senior Regional Manager & Head – Outreach Offices, NRDC; Syed S. Ahmed, Director & CEO, TechInvention Lifecare Limited; Dr. Sunil Kumar Raghav, Scientist F, ILS Bhubaneswar; Dr. Ashis Biswas, Professor, School of Basic Sciences, IIT Bhubaneswar, along with other distinguished guests.

The HSP Subunit Vaccine candidate, jointly developed by the premier institutions ILS and IIT Bhubaneswar, represents a significant advancement in India's efforts to combat Mycobacterium tuberculosis. This collaboration reflects the robustness of India's research ecosystem and its commitment to addressing critical public health challenges.

TechInvention Lifecare Limited, the licensed industry partner, will play a key role in translating this indigenous vaccine technology into a viable public health solution. With strong expertise in vaccine development, regulatory readiness, and global health innovation, TechInvention brings deep technical strength and established manufacturing capabilities.

This partnership ensures that the jointly developed vaccine candidate advances efficiently from research to product development, validation, and eventual commercialization. It strengthens India's mission to eliminate tuberculosis and underscores the transformative potential of indigenous, research-driven healthcare innovations for national and global health.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर

Indian Institute of Technology Bhubaneswar

Media/Publication	The Week		
Date	24 th November, 2025	Language	English
Headline	IIT Bhubaneswar transfer novel TB vaccine technology to TechInvention		
Link	https://www.theweek.in/wire-updates/national/2025/11/24/ces26-od-vaccine-tech.html		

Bhubaneswar, Nov 24 (PTI) The Bhubaneswar-based Indian Institute of Technology (IIT), the Institute of Life Sciences (ILS) along with the National Research Development Corporation (NRDC), have joined hands for the technology transfer and future commercialisation of a novel TB vaccine, officials said.

The three organisations signed a quadripartite license agreement (QLA) with TechInvention Lifecare Ltd here on Monday for the technology transfer and future commercialisation of ‘HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium tuberculosis’. The HSP Subunit Vaccine candidate was jointly developed by the premier institutions ILS and IIT Bhubaneswar, while NRDC identified and evaluated the technology and facilitated the licensing process to ensure its advancement, an official said.

TechInvention Lifecare Limited, the licensed industry partner, will play a key role in translating this indigenous vaccine technology into a viable public health solution, he said. Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, claiming 1.23 million lives in 2024 alone, as per the WHO report.

Ending the TB epidemic by 2030 is a key global health priority under the United Nations Sustainable Development Goals (SDGs), the IIT said in a statement on Monday.

However, the world continues to rely on the Bacillus Calmette Guerin (BCG) vaccine, developed over a century ago, which provides only limited protection mainly to infants and is largely ineffective in preventing pulmonary TB in adolescents and adults, it said.

To address this critical unmet need, a next-generation HSP Subunit Vaccine has been developed through collaborative research led by Ashis Biswas of IIT Bhubaneswar and Sunil Kumar Raghav of ILS, Bhubaneswar.

The IIT claimed that the vaccine candidate is designed to trigger strong humoral and cell-mediated immune responses while enhancing the protective efficacy of the existing BCG vaccine. This partnership ensures that the jointly developed vaccine candidate advances efficiently from research to product development, validation, and eventual commercialisation, as per the statement. It strengthens India’s mission to eliminate tuberculosis and underscores the transformative potential of indigenous, research-driven healthcare innovations for national and global health, the institute said.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The prameya		
Date	24 th November, 2024	Language	English
Headline	IIT Bhubaneswar, ILS transfer novel TB vaccine technology to TechInvention		
Link	https://www.prameyanews.com/iit-bhubaneswar-ils-transfer-novel-tb-vaccine-technology-to-techinvention		



Bhubaneswar, Nov 24: Indian Institute of Technology (IIT) Bhubaneswar and the Institute of Life Sciences (ILS), Bhubaneswar, along with the National Research Development Corporation (NRDC), have signed a Quadripartite License Agreement (QLA) with TechInvention Lifecare Limited for the technology transfer and future commercialization of a novel TB vaccine candidate titled “HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium tuberculosis.”

Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, claiming 1.23million lives in 2024alone, as reported by the WHO. Ending the TB epidemic by 2030 is a key global health priority under the United Nations Sustainable Development Goals (SDGs). However, the world continues to rely on the Bacillus Calmette Guérin (BCG) vaccine, developed over a century ago, which provides only limited protection mainly to infants and is largely ineffective in preventing pulmonary TB in adolescents and adults.

To address this critical unmet need, a next-generation HSP Subunit Vaccine has been developed through collaborative research led by Prof. Ashis Biswas of Indian Institute of Technology (IIT) Bhubaneswar and Dr. Sunil Kumar Raghav of Institute of Life Sciences (ILS), Bhubaneswar.

This vaccine candidate is designed to trigger strong humoral and cell-mediated immune responses while enhancing the protective efficacy of the existing BCG vaccine. In view of its significant public health potential, National Research Development Corporation (NRDC) proactively identified and evaluated this technology and facilitated the licensing process to ensure its advancement.

The technology exchange was held at ILS Bhubaneswar in the presence of several senior dignitaries including Dr. Debasis Dash, Director, ILS; Prof. Shreepad Karmalkar, Director, IIT Bhubaneswar; Prof. Dinakar Pasla, Dean (Sponsored Research & Industrial Consultancy), IIT Bhubaneswar; Dr. B. K. Sahu, Senior Regional Manager & Head – Outreach Offices, NRDC; Syed S. Ahmed, Director & CEO,



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

TechInvention Lifecare Limited; Dr. Sunil Kumar Raghav, Scientist F, ILS Bhubaneswar; Dr. Ashis Biswas, Professor, School of Basic Sciences, IIT Bhubaneswar, along with other distinguished guests.

The HSP Subunit Vaccine candidate, jointly developed by the premier institutions ILS and IIT Bhubaneswar, represents a significant advancement in India's efforts to combat Mycobacterium tuberculosis. This collaboration reflects the robustness of India's research ecosystem and its commitment to addressing critical public health challenges.

TechInvention Lifecare Limited, the licensed industry partner, will play a key role in translating this indigenous vaccine technology into a viable public health solution. With strong expertise in vaccine development, regulatory readiness, and global health innovation, TechInvention brings deep technical strength and established manufacturing capabilities.

This partnership ensures that the jointly developed vaccine candidate advances efficiently from research to product development, validation, and eventual commercialization. It strengthens India's mission to eliminate tuberculosis and underscores the transformative potential of indigenous, research-driven healthcare innovations for national and global health.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The Pragativadi		
Date	24 th November, 2025	Language	English
Headline	IIT Bhubaneswar and ILS Transfer Novel TB Vaccine Technology to TechInvention		
Link	https://pragativadi.com/iit-bhubaneswar-and-ils-transfer-novel-tb-vaccine-technology-to-techinvention/		



IIT Bhubaneswar and the Institute of Life Sciences (ILS), Bhubaneswar, achieved a major milestone in public health innovation by transferring novel TB vaccine technology to TechInvention Lifecare Limited.

The National Research Development Corporation (NRDC) facilitated the Quadripartite License Agreement (QLA), signed on November 24, 2025, to enable future commercialisation of the vaccine candidate titled “HSP Subunit Vaccine in Adjuvant (DDA) Against *Mycobacterium tuberculosis*.”

Tuberculosis remains one of the world’s deadliest infectious diseases, claiming 1.23 million lives in 2024, according to the WHO. Ending the TB epidemic by 2030 is a global priority under the United Nations Sustainable Development Goals (SDGs). However, the century-old Bacillus Calmette Guérin (BCG) vaccine offers limited protection, mainly to infants, and fails to prevent pulmonary TB in adolescents and adults.

To address this gap, Prof. Ashis Biswas of IIT Bhubaneswar and Dr Sunil Kumar Raghav of ILS led collaborative research to develop the HSP Subunit Vaccine. The candidate is designed to trigger strong



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

humoral and cell-mediated immune responses while enhancing the protective efficacy of the existing BCG vaccine.

The technology exchange ceremony at ILS Bhubaneswar witnessed the presence of senior dignitaries, including Dr Debasis Dash, Director, ILS; Prof. Shreepad Karmalkar, Director, IIT Bhubaneswar; Prof. Dinakar Pasla, Dean (Sponsored Research & Industrial Consultancy), IIT Bhubaneswar; Dr B. K. Sahu of NRDC; Syed S. Ahmed, CEO of TechInvention; and other distinguished guests.

TechInvention Lifecare Limited will play a crucial role in translating this indigenous vaccine into a viable public health solution. With expertise in vaccine development, regulatory readiness, and manufacturing, TechInvention ensures efficient advancement from research to commercialisation. This partnership strengthens India's mission to eliminate tuberculosis and highlights the transformative potential of indigenous, research-driven healthcare innovations.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The Odisha T.V		
Date	24 th November, 2025	Language	English
Headline	IIT-Bhubaneswar, ILS innovate next-gen tuberculosis vaccine HSP 16.3 DC4		
Link	https://odishatv.in/odisha/iit-bhubaneswar-ils-innovate-next-gen-tuberculosis-vaccine-hsp-163-dc4-10808921		

Technology transfer ceremony being held in Bhubaneswar Photograph: (OTV



A major scientific breakthrough has emerged from Bhubaneswar as a new tuberculosis (TB)-preventive vaccine is set to provide stronger protection than existing options. The [Institute of Life Sciences \(ILS\)](#), under BRIC, has developed a novel vaccine named HSP 16.3 DC4, offering the potential to significantly boost immunity against TB.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The ETV Bharat		
Date	24 th November, 2025	Language	Odia
Headline	ILS's 'HSP 16.3DC4' vaccine to provide protection against tuberculosis ILS has developed a vaccine against tuberculosis. BCG is the only approved vaccine for tuberculosis till now.		
Link	https://www.etvbharat.com/or/state/ils-invents-hsp-16-dot-3dc4-a-protective-shield-against-tuberculosis-odisha-news-ors25112404718		



ଭୁବନେଶ୍ୱର: ଇନ୍‌ଷ୍ଟିଚ୍ୟୁଟ୍ ଅଫ୍ ଲାଇଫ୍ ସାଇନ୍ସ- ILS ଉଦ୍ଭାବନ କଲା ଯନ୍ତ୍ରା (ଟିବି) ପ୍ରତିରୋଧକ ଟିକା। ଟିବି ବା ଯନ୍ତ୍ରାରୁ ସୁରକ୍ଷା ପାଇଁ ଏକ ଟିକା, ଯାହା ପରବର୍ତ୍ତୀ ଜେନେରେସନ୍ ଭ୍ୟାକ୍ସିନ୍ ଭାବେ ବେଶ୍ ଫଳପ୍ରସ୍ତ ହେବ। BRIC- ଇନ୍‌ଷ୍ଟିଚ୍ୟୁଟ୍ ଅଫ୍ ଲାଇଫ୍ ସାଇନ୍ସ ବୈଜ୍ଞାନିକମାନେ ଉଦ୍ଭାବନ କରିଥିବା ଏହି ଭ୍ୟାକ୍ସିନ୍ ହେଉଛି, ‘HSP 16.3DC4’ । ଏଥିରେ ଆଇଆଇଟି ଭୁବନେଶ୍ୱର ପକ୍ଷରୁ ସମସ୍ତ ପ୍ରକାର ବୈଷୟିକ ସହଯୋଗିତା ରହିଛି। ଏହି ଭ୍ୟାକ୍ସିନ୍‌ର ଫର୍ମୁଲା ଓ ଟେକ୍ନୋଲୋଜି, ଟିକା ପ୍ରସ୍ତୁତକାରୀ ଅନୁଷ୍ଠାନକୁ ହସ୍ତାନ୍ତର କରାଯାଇଛି। ଏହି ଟେକ୍ନୋଲୋଜିକୁ ନେଇ ଆଗ୍ରହୀ ଔଷଧ ପ୍ରସ୍ତୁତକାରୀ କମ୍ପାନି ‘HSP 16.3DC4’ ଭ୍ୟାକ୍ସିନ୍ ବା ଟିକା ପ୍ରସ୍ତୁତ କରିବେ ଟିକା ଗବେଷଣାପାଇ12 ବର୍ଷ ସମୟ ଲାଗିଥିଲା:-

ଗବେଷଣା ସମୟରେ ଏହି ‘HSP 16.3DC4’ ଭ୍ୟାକ୍ସିନ୍ ମୂଷାଙ୍କଠାରେ ସଫଳତାର ସହ କାର୍ଯ୍ୟ କରିଛି। ଏହା ଆଗକୁ ଯନ୍ତ୍ରା (ଟିବି) ପ୍ରତିରୋଧକ ଦିଗରେ ଫଳପ୍ରସ୍ତ ହେବ। ଦେଶ ତଥା ରାଜ୍ୟକୁ ଟିବି ମୁକ୍ତ କରିବା ଦିଗରେ ସୁରକ୍ଷା କବଚ ଭଳି କାର୍ଯ୍ୟ କରିବ ‘HSP 16.3DC4’। ଏହି ଟିକାର ପରୀକ୍ଷା 12 ବର୍ଷ ଧରି କରାଯାଇଥିଲା। ଯାହା କେବଳ ମୂଷା ଉପରେ ପରୀକ୍ଷଣ ପାଇଁ 5ରୁ 7 ବର୍ଷ ସମୟ ଲାଗିଥିଲା। ଏହା ପୂର୍ବରୁ 2 ବର୍ଷ ଧରି ଟିକା ଉପରେ ପରୀକ୍ଷା କରାଯାଇଥିଲା। ଏପରି ଦେଖିବାକୁ ଗଲେ ଏହି ଟିକା ପାଇଁ ସର୍ବ ମୋଟ ଆକାରରେ 12 ବର୍ଷ ସମୟ ଲାଗିଥିଲା।



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

ଯଜ୍ଞା ବିରୋଧରେ ସୁରକ୍ଷା କବଚ:-

ବର୍ତ୍ତମାନ ବାସିଲସ୍ କାଲମେଟ୍-ଗୁଏରିନ୍- BCG ହେଉଛି, ଏପର୍ଯ୍ୟନ୍ତ ଯଜ୍ଞା ପାଇଁ ଏକ ମାତ୍ର ଅନୁମୋଦିତ ଟୀକା। ତେବେ ତା ତୁଳନାରେ ଏହି ‘HSP 16.3DC4’ ଟୀକା ବହୁତ ପ୍ରଭାବୀ ଅଟେ। ଏହି ଟୀକା କୋଷିକାର ଟି-ସେଲ୍ ମେମୋରୀ ଓ ବି-ସେଲ୍ ମେମୋରୀକୁ ନିରନ୍ତର ସକ୍ରିୟ ରଖୁଥାଏ। ଯାହା ପଳରେ ନିରନ୍ତର ଜୀବାଣୁ ମାରିବା ଦିଗରେ ସଂଗ୍ରାମ କରିଥାଏ। ଏହା ଯୁବପୀଡ଼ିଙ୍କ କ୍ଷେତ୍ରରେ ଭଲ କାର୍ଯ୍ୟ କରିବ। ଯାହା ଲୋକଙ୍କୁ ସ୍ଥାୟୀ ଯଜ୍ଞା ପ୍ରତିରୋଧକ କ୍ଷମତା ଓ ପ୍ରତିରକ୍ଷା ଦେଇପାରିବ। ଏହା ଜୀବାଣୁ ବିରୋଧରେ ଦୀର୍ଘ ସମୟ ଧରି ରୋଗ ପ୍ରତିରୋଧକ ଶକ୍ତି ବୃଦ୍ଧି କରିବ। ଏହା କୋଷୀୟ ଏବଂ ହ୍ୟୁମୋରାଲ୍ ପ୍ରତିକ୍ରିୟା ଉଭୟକୁ ବୃଦ୍ଧି କରି ପଲ୍ମୋନାରୀ ଜୀବାଣୁ ବିରୋଧରେ ସଂଗ୍ରାମ କରିବ।

2025 ସୁଧା ଟିବି ମୁକ୍ତ ପ୍ରକାଶ:-

୨୦୨୫ ସୁଧା ସମାଜକୁ ଟିବି ମୁକ୍ତ କରିବା ଲାଗି କେନ୍ଦ୍ର ଓ ରାଜ୍ୟ ସରକାର ଅଭିଯାନ ଜାରି ରଖିଛନ୍ତି। ଟିବି ରୋଗୀ ଚିହ୍ନଟ ଓ ଚିକିତ୍ସା ଦିଗରେ ଜୋରଦାର ଉଦ୍ୟମ ଜାରି ରଖି ରାଜ୍ୟ ସ୍ବାସ୍ଥ୍ୟ ବିଭାଗର ଟିବି ସେଲ୍, ରାଜ୍ୟରେ ବ୍ୟାପକ ପଦକ୍ଷେପ ସତ୍ତ୍ୱେ ମଧ୍ୟ ବଢ଼ୁଛି ଯଜ୍ଞା ରୋଗୀଙ୍କ ସଂଖ୍ୟା। ମାଲନ୍ୟୁଟ୍ରିସନ ଯୋଗୁ ରାଜ୍ୟରେ ବ୍ୟାପୁଛି ଯଜ୍ଞା ରୋଗ ବା ଟିବି।

ରାଜ୍ୟରେ ଟିବି ବା ଯଜ୍ଞା ରୋଗୀଙ୍କ ସଂଖ୍ୟା କେତେ:-

ରାଜ୍ୟରେ ଗତବର୍ଷ ୬୨ ହଜାର ଯଜ୍ଞା ରୋଗୀ ଚିହ୍ନଟ କରାଯାଇଥିଲା। ଚଳିତ ବର୍ଷ ୧୦୦ ଦିନର ସ୍ୱତନ୍ତ୍ର ଟିବି କ୍ୟାମ୍ପେନରେ ରାଜ୍ୟରେ ନୂଆ ୧୨ ହଜାର ୨୪୫ ଯଜ୍ଞା ରୋଗୀ ଚିହ୍ନଟ ହୋଇଛନ୍ତି। ତେବେ ଯଜ୍ଞା ମୃତ୍ୟୁ ହାର ରାଜ୍ୟରେ ୬ ପ୍ରତିଶତରୁ କମ୍ ହୋଇ ଏବେ ୪ ପ୍ରତିଶତରେ ପହଞ୍ଚିଛି।

ଯଜ୍ଞା ରୋଗ ପାଇଁ ବିଭାଗ ପକ୍ଷରୁ କ’ଣ ରହିଛି ସୁବିଧା:-

ଯଜ୍ଞା ରୋଗ ପାଇଁ ଫୁଡ୍ ବାସ୍କେଟ୍ ବ୍ୟବସ୍ଥା ସହ ୬ ମାସିଆ ଲଞ୍ଜେନ୍ସିଭ୍ ଥେରାପି ଦିଆଯାଉଛି। ୨୦୨୫ ଡିସେମ୍ବର ସୁଦ୍ଧା ଓଡ଼ିଶାକୁ ଟିବି ମୁକ୍ତ କରିବା ପାଇଁ ଟାର୍ଗେଟ୍ ଦିଆଯାଇଛି। କିନ୍ତୁ ବର୍ଷକୁ ଏତେ ସଂଖ୍ୟକ ରୋଗୀ ବାହାରୁଥିବାରୁ ଏହି ଟାର୍ଗେଟ୍ କିଭଳି ହାସଲ ହୋଇପାରିବ, ତାକୁ ନେଇ ପ୍ରଶ୍ନ ଉଠିଛି। ଏହାକୁ ଦୃଷ୍ଟିରେ ରଖି କାର୍ଯ୍ୟ କରାଯାଉଛି ବୋଲି ସ୍ବାସ୍ଥ୍ୟ ବିଭାଗର ଟିବି ସେଲ୍ ପକ୍ଷରୁ କୁହାଯାଇଛି।

ଟିବି ସଂକ୍ରମିତଙ୍କ ପାଇଁ କ’ଣ ରହିଛି ସରକାରୀ ସୁବିଧା:-

ରାଜ୍ୟରେ ଟିବି ସଂକ୍ରମିତଙ୍କ ପାଇଁ ସରକାରଙ୍କ ପକ୍ଷରୁ ରହିଛି ଅନେକ ସୁବିଧା। ସମସ୍ତ ସ୍ବାସ୍ଥ୍ୟକେନ୍ଦ୍ର ଓ ସମସ୍ତ ହେଲ୍ଥ ଓ ଡ୍ରେଲନେସ ସେଣ୍ଟରରେ ଚିହ୍ନଟ ହୋଇଥିବା ଯଜ୍ଞା ରୋଗୀଙ୍କୁ ବିନା ମୂଲ୍ୟରେ ରୋଗ ନିରୂପଣ କରାଯାଉଛି। ଏହାସହିତ ଉନ୍ନତମାନର ଔଷଧ ମଧ୍ୟ ଦିଆଯାଉଛି। ମାଲକ୍ରୋସୋପି ଏବଂ ଏକ୍ସରେ ସହିତ ମୋଲେକୁଲାର ପଦ୍ଧତି ଦ୍ୱାରା କପ୍ ପରୀକ୍ଷା ସୁବିଧାକୁ ଧୀରେ ଧୀରେ ସମସ୍ତ ବ୍ଲକକୁ ସଂପ୍ରସାରିତ କରାଯାଉଛି। ‘ଏନପିଝାଲ୍’ ଅଧୀନରେ ଚିହ୍ନଟ ହୋଇ ଚିକିତ୍ସିତ ହେଉଥିବା ପ୍ରତ୍ୟେକ ଯଜ୍ଞା ରୋଗୀଙ୍କୁ ମାସିକ ୫ ଶହ ଟଙ୍କା ଭତ୍ତା, ଚିକିତ୍ସା ବାବଦରେ ଦିଆଯାଉଛି। ଚିକିତ୍ସା ଶେଷ ହେବା ପର୍ଯ୍ୟନ୍ତ ରୋଗୀଙ୍କ ବ୍ୟାଙ୍କ ଖାତା ଜରିଆରେ ଏହି ରାଶି ପ୍ରଦାନ କରାଯାଉଛି।



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

ରାଜ୍ୟରେ ଟିବି ସଂକ୍ରମିତଙ୍କ ସ୍ଥିତି କିଭଳି:-

ସ୍ୱାସ୍ଥ୍ୟ ବିଭାଗର ତଥ୍ୟ ଅନୁସାରେ, ୨୦୧୫ ଠାରୁ ବାର୍ଷିକ ଯକ୍ଷ୍ମା ରୋଗ ହାର ୧୮ ପ୍ରତିଶତ ହ୍ରାସ ପାଇଛି। ୨୦୨୩ ସୁଦ୍ଧା ମୃତ୍ୟୁ ହାର ୨୨ ପ୍ରତିଶତ ହ୍ରାସ ପାଇଛି। ପ୍ରତି ଏକ ଲକ୍ଷ ଜନସଂଖ୍ୟାରେ ଯକ୍ଷ୍ମା ରୋଗୀଙ୍କ ସଂଖ୍ୟା ୨୦୧୫ ମସିହାରେ ୨୩୭ରୁ ୨୦୨୩ ମସିହାରେ ୧୯୫କୁ ହ୍ରାସ ପାଇଛି। ସେହିପରି ଭାବେ ଏକ ଲକ୍ଷ ଜନସଂଖ୍ୟାରେ ୨୦୧୫ ମସିହାରେ ୨୮ ଜଣଙ୍କ ଟିବିରେ ମୃତ୍ୟୁ ଘଟିଥିବା ବେଳେ ୨୦୨୩ ମସିହାରେ ୨୨ ଜଣଙ୍କ ମୃତ୍ୟୁ ଘଟିଛି।

ରାଜ୍ୟରେ କେତେ ଅଛନ୍ତି ଟିବି ରୋଗୀ:-

ଟିବି ପାଇଁ ବର୍ତ୍ତମାନ ସମୟରେ ରାଜ୍ୟର ୧୯ଟି ଜିଲ୍ଲାକୁ ଅଧିକ ମାତ୍ରାରେ ଫୋକସ କରାଯାଉଛି । ବଲାଙ୍ଗିର, ବରଗଡ଼, ଭଦ୍ରକ, ବୌଦ୍ଧ, କଟକ, ଦେବଗଡ଼, ଗଞ୍ଜାମ, ଜଗତସିଂହପୁର, କଳାହାଣ୍ଡି, କନ୍ଧମାଳ, କେନ୍ଦ୍ରାପଡ଼ା, କୋରାପୁଟ, ମାଲକାନଗିରି, ମୟୂରଭଞ୍ଜ, ପୁରୀ, ସୋନପୁର, ରାୟଗଡ଼ା ଓ ସୁନ୍ଦରଗଡ଼ ଆଦି ଜିଲ୍ଲା ଅଧିକ ଫୋକସରେ ରହିଛି।

୨୦୨୪ ସୁଦ୍ଧା ରାଜ୍ୟର ଏସମସ୍ତ ଜିଲ୍ଲାରେ ଟିକ୍କଟ ହୋଇଥିବା ଯକ୍ଷ୍ମା ରୋଗୀ-

ବଲାଙ୍ଗିର ଜିଲ୍ଲାରେ ୧୨୧୧ ଟିବି ରୋଗୀ ଟିକ୍କଟ ହୋଇଥିବା ବେଳେ ବରଗଡ଼ ଜିଲ୍ଲାରେ ୯୪୪ ଜଣ, ଭଦ୍ରକ ଜିଲ୍ଲାରେ ୬୮୪, ବୌଦ୍ଧ ଜିଲ୍ଲାରେ ୧୭୬, କଟକ ଜିଲ୍ଲାରେ ୧୬୬୧, ଦେବଗଡ଼ ଜିଲ୍ଲାରେ ୧୯୯, ଗଞ୍ଜାମ ଜିଲ୍ଲାରେ ୪୧୭୨, ଜଗତସିଂହପୁର ଜିଲ୍ଲାରେ ୨୯୮, କଳାହାଣ୍ଡି ଜିଲ୍ଲାରେ ୧୧୦୦, କନ୍ଧମାଳ ଜିଲ୍ଲାରେ ୯୬୮, କେନ୍ଦ୍ରାପଡ଼ା ଜିଲ୍ଲାରେ ୬୧୨, କେନ୍ଦୁଝର ଜିଲ୍ଲାରେ ୨୩୩୦, କୋରାପୁଟ ଜିଲ୍ଲାରେ ୧୪୬୮, ମାଲକାନଗିରି ଜିଲ୍ଲାରେ ୫୯୫, ମୟୂରଭଞ୍ଜ ଜିଲ୍ଲାରେ ୩୯୦୬, ପୁରୀ ଜିଲ୍ଲାରେ ୭୭୮, ସୋନପୁର ଜିଲ୍ଲାରେ ୨୪୭, ରାୟଗଡ଼ା ଜିଲ୍ଲାରେ ୧୧୬୭, ସୁନ୍ଦରଗଡ଼ ଜିଲ୍ଲାରେ ୧୯୧୪ ଟିବି ରୋଗୀ ଟିକ୍କଟ କରାଯାଇଛି। ତେବେ ରାଜ୍ୟର ମୋଟ ୧୯ଟି ଜିଲ୍ଲାରେ ବିଶେଷ ଭାବେ ପାଖାପାଖି ୨୪ ହଜାର ୪୩୦ ଜଣ ଟିବି ରୋଗୀ ରହିଥିବା, ସ୍ୱାସ୍ଥ୍ୟ ବିଭାଗ ପକ୍ଷରୁ ସୂଚନା ଦିଆଯାଇଛି।



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The Orissa Post		
Date	24 th November, 2025	Language	English
Headline	IIT Bhubaneswar, ILS sign pact to commercialise new TB vaccine		
Link	https://www.orissapost.com/iit-bhubaneswar-ils-sign-pact-to-commercialise-new-tb-vaccine/amp/		



Bhubaneswar: The Bhubaneswar-based Indian Institute of Technology (IIT), the Institute of Life Sciences (ILS), along with the National Research Development Corporation (NRDC), have joined hands for the technology transfer and future commercialisation of a novel TB vaccine, officials said.

The three organisations signed a quadripartite license agreement (QLA) with TechInvention Lifecare Ltd, Monday, for the technology transfer and future commercialisation of ‘HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium tuberculosis’.

The HSP Subunit Vaccine candidate was jointly developed by the premier institutions ILS and IIT Bhubaneswar, while NRDC identified and evaluated the technology and facilitated the licensing process to ensure its advancement, an official said.

TechInvention Lifecare Limited, the licensed industry partner, will play a key role in translating this indigenous vaccine technology into a viable public health solution, he said.

Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, claiming 1.23 million lives in 2024 alone, as per the WHO report.

Ending the TB epidemic by 2030 is a key global health priority under the United Nations Sustainable Development Goals (SDGs), the IIT said in a statement Monday.

However, the world continues to rely on the Bacillus Calmette Guerin (BCG) vaccine, developed over a century ago, which provides only limited protection mainly to infants and is largely ineffective in preventing pulmonary TB in adolescents and adults, it said.

To address this critical unmet need, a next-generation HSP Subunit Vaccine has been developed through collaborative research led by Ashis Biswas of IIT Bhubaneswar and Sunil Kumar Raghav of ILS, Bhubaneswar.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर
Indian Institute of Technology Bhubaneswar

The IIT claimed that the vaccine candidate is designed to trigger strong humoral and cell-mediated immune responses while enhancing the protective efficacy of the existing BCG vaccine.

This partnership ensures that the jointly developed vaccine candidate advances efficiently from research to product development, validation, and eventual commercialisation, as per the statement.

It strengthens India's mission to eliminate tuberculosis and underscores the transformative potential of indigenous, research-driven healthcare innovations for national and global health, the institute said.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The Telegraph Online		
Date	24 th November, 2025	Language	English
Headline	IIT Bhubaneswar and ILS create new HSP subunit TB vaccine to enhance BCG protection		
Link	https://www.telegraphindia.com/amp/india/iit-bhubaneswar-and-ils-develop-hsp-subunit-vaccine-to-fight-tuberculosis-in-india-prnt/cid/2134600		

Indian Institute of Technology Bhubaneswar and the Institute of Life Sciences (ILS), Bhubaneswar have jointly developed a vaccine to combat tuberculosis (TB).

The HSP subunit vaccine candidate represents a significant step forward in India's fight against *Mycobacterium tuberculosis*. "This collaboration reflects the robustness of India's research ecosystem and its commitment to addressing critical public health challenges," a release from IIT said.

TB remains one of the world's deadliest infectious diseases, claiming 1.23 million lives in 2024 alone, according to the WHO. Ending the TB epidemic by 2030 is a key global health priority under the United Nations Sustainable Development Goals.

Currently, the Bacillus Calmette Guérin (BCG) vaccine, developed over a century ago, offers limited protection, mainly to infants, and is largely ineffective in preventing pulmonary TB in adolescents and adults.

"To address this critical unmet need, a next-generation HSP Subunit Vaccine has been developed through collaborative research led by Prof Ashis Biswas of IIT Bhubaneswar and Dr Sunil Kumar Raghav of ILS Bhubaneswar," the release said.

For commercial use, IIT Bhubaneswar and ILS, along with the National Research Development Corporation (NRDC), have signed a Quadripartite License Agreement with TechInvention Lifecare Limited to transfer technology and develop the vaccine candidate, titled "HSP Subunit Vaccine in Adjuvant (DDA) Against *Mycobacterium tuberculosis*."

The vaccine candidate is designed to trigger strong humoral and cell-mediated immune responses while enhancing BCG's protective efficacy. NRDC facilitated the licensing process to ensure its advancement.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर
Indian Institute of Technology Bhubaneswar

Media/Publication	The Press Trust of India		
Date	25 th November, 2025	Language	English
Headline	IIT Bhubaneswar, transfer novel TB vaccine technology to TechInvention		
Link	https://www.ptinews.com/editor-detail/iit-bhubaneswar--transfer-novel-tb-vaccine-technology-to-techinvention/3127430		

BHUBANESWAR: (Nov 24) The Bhubaneswar-based Indian Institute of Technology (IIT), the Institute of Life Sciences (ILS) along with the National Research Development Corporation (NRDC), have joined hands for the technology transfer and future commercialisation of a novel TB vaccine, officials said.

The three organisations signed a quadripartite license agreement (QLA) with TechInvention Lifecare Ltd here on Monday for the technology transfer and future commercialisation of ‘HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium tuberculosis’.

The HSP Subunit Vaccine candidate was jointly developed by the premier institutions ILS and IIT Bhubaneswar, while NRDC identified and evaluated the technology and facilitated the licensing process to ensure its advancement, an official said.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The Indian News		
Date	25 th November, 2025	Language	English
Headline	Odisha: IIT Bhubaneswar signs agreement for Novel TB vaccine technology		
Link	https://indianews.com.au/odisha-iit-bhubaneswar-signs-agreement-for-novel-tb-vaccine-technology/		



Bhubaneswar, Nov 24 (IANS) Taking a major stride toward advancing indigenous TB vaccine research, IIT Bhubaneswar, the Institute of Life Sciences (ILS), and the National Research Development Corporation (NRDC) have formalised a Quadripartite License Agreement with TechInvention Lifecare Limited.

The agreement paves the way for technology transfer and potential commercialisation of a promising new vaccine candidate, “HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium tuberculosis.”

The agreement aims to advance the vaccine from laboratory research to product development and eventual commercial deployment.

According to the World Health Organization, TB claimed 1.23 million lives in 2024, making it one of the world’s deadliest infectious diseases.

“However, the world continues to rely on the Bacillus Calmette Guérin (BCG) vaccine, developed over a century ago, which provides only limited protection mainly to infants and is largely ineffective in preventing pulmonary TB in adolescents and adults.

“To address this critical unmet need, a next-generation HSP Subunit Vaccine has been developed through collaborative research led by Prof. Ashis Biswas of IIT, Bhubaneswar and Dr Sunil Kumar Raghav of ILS, Bhubaneswar,” reads a press note issued by the ILS.

This vaccine candidate is designed to trigger strong humoral and cell-mediated immune responses while enhancing the protective efficacy of the existing BCG vaccine.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर
Indian Institute of Technology Bhubaneswar

In view of its significant public health potential, the NRDC proactively identified and evaluated this technology and facilitated the licensing process to ensure its advancement.

“The HSP Subunit Vaccine candidate, jointly developed by the premier institutions ILS and IIT Bhubaneswar, represents a significant advancement in India’s efforts to combat Mycobacterium tuberculosis. This collaboration reflects the robustness of India’s research ecosystem and its commitment to addressing critical public health challenges,” the ILS further added.

Media/Publication	The HINDU		
Date	25 th November, 2025	Language	English
Headline	New TB vaccine for adolescents, adults ready for commercialisation		
Link	https://www.thehindu.com/sci-tech/health/new-tb-vaccine-for-adolescents-adults-ready-for-commercialisation/article70317633.ece/amp/		

Indian Institute of Technology (IIT) Bhubaneswar and the Institute of Life Sciences (ILS), Bhubaneswar, under Department of Biotechnology, along with the National Research Development Corporation (NRDC), have signed a quadripartite license agreement (QLA) with TechInvention Lifecare Limited for the technology transfer and future commercialisation of the novel TB vaccine.

According to ILS, tuberculosis remains one of the world's deadliest infectious diseases, claiming 1.23 million lives in 2024 alone, as reported by the WHO.

“Ending the TB epidemic by 2030 is a key global health priority under the United Nations Sustainable Development Goals (SDGs). However, the world continues to rely on the Bacillus Calmette Guérin (BCG) vaccine, developed over a century ago, which provides only limited protection mainly to infants and is largely ineffective in preventing pulmonary TB in adolescents and adults,” it said.

To address this critical unmet need, a next-generation HSP Subunit Vaccine has been developed through collaborative research led by Prof Ashis Biswas of IIT, Bhubaneswar and Sunil Kumar Raghav of ILS, Bhubaneswar, the institute said.

“This vaccine candidate is designed to trigger strong humoral and cell-mediated immune responses while enhancing the protective efficacy of the existing BCG vaccine. In view of its significant public health potential, NRDC proactively identified and evaluated this technology and facilitated the licensing process to ensure its advancement,” said the national level institutes involved in development of the vaccine.

The technology exchange was held at ILS Bhubaneswar in the presence of several senior dignitaries including Debasis Dash, ILS Director, Shreepad Karmalkar, IIT Director, B. K. Sahu, Senior Regional Manager and Head (Outreach Offices) of NRDC and Syed S. Ahmed, Director and CEO of TechInvention Lifecare Limited.

“The HSP Subunit Vaccine candidate, jointly developed by the premier institutions ILS and IIT Bhubaneswar, represents a significant advancement in India's efforts to combat Mycobacterium tuberculosis. This collaboration reflects the robustness of India's research ecosystem and its commitment to addressing critical public health challenges,” a statement issued by institutes said.

It pointed out that TechInvention, the licensed industry partner, was committed to translating this indigenous vaccine technology into a viable public health solution.

The joint statement said this partnership ensures that the jointly developed vaccine candidate advances efficiently from research to product development, validation, and eventual commercialisation.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The Times of India		
Date	25 th November, 2025	Language	English
Headline	TB vaccine's tech transferred to private firm		
Link	https://timesofindia.indiatimes.com/city/bhubaneswar/tb-vaccines-tech-transferred-to-private-firm/amp_articleshow/125547025.cms		

Bhubaneswar: The Institute of Life Sciences (ILS) Bhubaneswar and IIT Bhubaneswar on Monday transferred the technology of a potential vaccine candidate developed for tuberculosis (TB) to a firm. The company will conduct further clinical trials and commercialize the vaccine.

The existing BCG vaccine provides only limited protection and mainly to infants. It is largely ineffective in preventing pulmonary TB in adolescents and adults. However, this vaccine will help adolescents and adults, apart from enhancing the efficacy of the existing BCG vaccine.

Both institutions, along with the National Research Development Corporation (NRDC), signed a quadripartite licence agreement with TechInvention Lifecare Limited for technology transfer and future commercialisation of a TB vaccine candidate titled 'HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium tuberculosis.'

Ashis Biswas, professor, school of basic sciences, IIT Bhubaneswar, said he started working on vaccine candidates in 2012. "After analysing several variants, I found one which became a potential vaccine candidate later. I met Sunil Kumar Raghav, ILS scientist, in 2020 and started collaborating with the ILS Bhubaneswar team to conduct a pre-clinical study of the vaccine candidate," Biswas said.

Raghav said they completed animal trials as part of the pre-clinical study. "We saw the vaccine candidate is very effective. It reduces bacterial load and increases immunity cells for long-term protection of lungs," Raghav said. TNN

Media/Publication	The New Indian Express		
Date	25 th November, 2025	Language	English
Headline	IIT-BBS & ILS hand new TB vaccine tech to TechInvention		
Link	https://www.newindianexpress.com/amp/story/states/odisha/2025/Nov/25/iit-bbs-ils-hand-new-tb-vaccine-tech-to-techinvention		

BHUBANESWAR: Indian Institute of Technology (IIT) Bhubaneswar and Institute of Life Sciences (ILS) along with National Research Development Corporation (NRDC) on Monday signed a quadripartite licence agreement (QLA) with TechInvention Lifecare Limited for the technology transfer and commercialisation of a novel TB vaccine against Mycobacterium tuberculosis.

Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, claiming 1.23 million lives in 2024 alone. The next-generation HSP subunit vaccine has been developed through a collaborative research led by Prof Ashis Biswas of IIT-BBS and Dr Sunil Kumar Raghav of ILS-BBS.

This vaccine candidate has been designed to trigger strong humoral and cell-mediated immune responses while enhancing the protective efficacy of the existing BCG vaccine.

In view of its significant public health potential, NRDC evaluated this technology and facilitated the licencing process to ensure its commercialisation.

Prof Biswas said this is a protein subunit vaccine developed as part of a joint collaboration. “The protein was first developed at the IIT lab and then underwent preclinical trials on mice models at ILS, which tested the efficacy levels. Until now BCG was the only vaccine against TB. The new vaccine if administered after BCG, will act as a booster dose with higher efficiency,” he said.

As per the agreement, TechInvention, the licensed industry partner, will help translate this indigenous vaccine technology into a viable public health solution. With strong expertise in vaccine development, regulatory readiness, and global health innovation, TechInvention is expected to complete phase-I and II clinical trials within next four to five years.

“This partnership ensures that the jointly developed vaccine candidate advances efficiently from research to product development, validation and eventual commercialisation. It strengthens India’s mission to eliminate tuberculosis and underscores the transformative potential of indigenous, research-driven healthcare innovations for national and global health,” said ILS director Debasis Dash.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The Janta se Rishta		
Date	25 th November, 2025	Language	Hindi
Headline	ILS and IIT-Bhubaneswar collaborate on new TB vaccine		
Link	https://jantaserishta.com/amp/local/odisha/ils-iit-bhubaneswar-collaborate-on-new-tuberculosis-vaccine-4399774		



भुवनेश्वर : एक बड़ी कामयाबी में, इंस्टिट्यूट ऑफ़ लाइफ साइंसेज़ (ILS), भुवनेश्वर ने ट्यूबरकुलोसिस (TB) के लिए अगली पीढ़ी की सबयूनिट वैक्सीन बनाई है। IIT-भुवनेश्वर के साथ मिलकर बनाई गई 'Hsp16.3C4' नाम की वैक्सीन सफल प्री-क्लिनिकल ट्रायल के बाद टेक्नोलॉजी ट्रांसफर के लिए तैयार है।

TB दुनिया की सबसे जानलेवा संक्रामक बीमारियों में से एक है, जिसने अकेले पिछले साल 12 लाख से ज़्यादा जानें लीं। अभी बैसिलस कैलमेट ग्यूरिन (BCG) वैक्सीन ही एकमात्र लाइसेंसड इम्यूनाइज़ेशन स्ट्रेटेजी है जिसका इस्तेमाल सभी देशों में TB की रोकथाम के लिए किया जा रहा है। ILS के सीनियर साइंटिस्ट डॉ. सुनील कुमार राघव और IIT-भुवनेश्वर के प्रोफ़ेसर आशीष बिस्वास की अगुवाई में मिलकर की गई रिसर्च से HSP सबयूनिट वैक्सीन बनी, जिसे भारत में TB के खिलाफ़ पहली वैक्सीन माना जाता है।

हालांकि BCG बच्चों को थोड़ी सुरक्षा देता है, लेकिन यह कम असर, अलग-अलग सुरक्षा नतीजों और टिकाऊ मेमोरी रिस्पॉन्स की कमी के कारण पूरी सुरक्षा देने में नाकाम रहा है। यह किशोरों और बड़ों में पल्मोनरी TB, जो बीमारी का सबसे ज़्यादा फैलने वाला रूप है, को भी रोकने में नाकाम रहता है।

इस कमी को पूरा करने और सभी उम्र के लोगों के लिए वैक्सीन बनाने पर रिसर्च दशकों से फोकस रही है। चूहों के मॉडल पर किए गए प्री-क्लिनिकल ट्रायल सफल रहे हैं क्योंकि वैक्सीनेशन के बाद ब्लड ग्लूकोज, रीनल फंक्शनल मार्कर (यूरिया और क्रिएटिनिन) और लिपिड प्रोफाइल कंपोनेंट (कोलेस्ट्रॉल और ट्राइग्लिसराइड्स) जैसे नॉर्मल बायोकेमिकल पैरामीटर में कोई टॉक्सिसिटी सिग्नल नहीं देखा गया।



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The Sambad		
Date	25 th November, 2025	Language	English
Headline	IIT Bhubaneswar signs agreement for TB vaccine		
Link	https://sambadenglish.com/latest-news/iit-bhubaneswar-signs-agreement-for-tb-vaccine-10809365/amp		



Bhubaneswar: Taking a major stride toward advancing indigenous [TB](#) vaccine research, [IIT Bhubaneswar](#), the Institute of Life Sciences (ILS), and the National Research Development Corporation (NRDC) have formalised a Quadripartite License Agreement with TechInvention Lifecare Limited.

The agreement paves the way for technology transfer and potential commercialisation of a promising new vaccine candidate, “HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium [tuberculosis](#).”

The agreement aims to advance the vaccine from laboratory research to product development and eventual commercial deployment.

Also read: [NaMo Semiconductor Lab at IIT Bhubaneswar to boost India's chip design ecosystem: MeitY](#)

According to the World [health](#) Organisation, TB claimed 1.23 million lives in 2024, making it one of the world's deadliest infectious diseases.

“However, the world continues to rely on the Bacillus Calmette Guérin (BCG) vaccine, developed over a century ago, which provides only limited protection mainly to infants and is largely ineffective in preventing pulmonary TB in adolescents and adults.

“To address this critical unmet need, a next-generation HSP Subunit Vaccine has been developed through collaborative research led by Prof. Ashis Biswas of IIT, Bhubaneswar and Dr Sunil Kumar Raghav of ILS, Bhubaneswar,” reads a press note issued by the ILS.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

About the vaccine

This vaccine candidate is designed to trigger strong humoral and cell-mediated immune responses while enhancing the protective efficacy of the existing BCG vaccine.

In view of its significant public health potential, the NRDC proactively identified and evaluated this technology and facilitated the licensing process to ensure its advancement.

“The HSP Subunit Vaccine candidate, jointly developed by the premier institutions ILS and IIT Bhubaneswar, represents a significant advancement in India’s efforts to combat Mycobacterium tuberculosis. This collaboration reflects the robustness of India’s research ecosystem and its commitment to addressing critical public health challenges,” the ILS further added.

TechInvention Lifecare Limited, the licensed industry partner, will play a key role in translating this indigenous vaccine technology into a viable public health solution.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर
Indian Institute of Technology Bhubaneswar

Media/Publication	The wral		
Date	25 th November, 2025	Language	English
Headline	India's Indigenous TB Vaccine: IIT Bhubaneswar Unleashes AI and Biotech for a New Era of Disease Defense		
Link	https://markets.financialcontent.com/wral/article/tokenring-2025-11-24-indias-indigenous-tb-vaccine-iit-bhubaneswar-unleashes-ai-and-biotech-for-a-new-era-of-disease-defense		

In a monumental leap for global public health, the Indian Institute of Technology (IIT) Bhubaneswar, in collaboration with the Institute of Life Sciences (ILS) Bhubaneswar, has spearheaded the development of India's first indigenous, next-generation subunit vaccine against tuberculosis (TB). This groundbreaking initiative, culminating in the 'Hsp16.3C4' vaccine, has successfully completed pre-clinical trials, showcasing robust immune responses without adverse effects. This advancement marks a critical turning point in the relentless global battle against TB, a disease that continues to claim millions of lives annually, and highlights the transformative power of integrating advanced biotechnology with cutting-edge artificial intelligence.

The immediate significance of this breakthrough cannot be overstated. With the existing Bacillus Calmette Guérin (BCG) vaccine offering limited protection, particularly against pulmonary TB in adults and adolescents, the Hsp16.3C4 vaccine emerges as a beacon of hope. Its unique design, which does not interfere with the BCG vaccine's biology, positions it as a potential standalone immunization or a crucial booster, promising enhanced and broader protection. The recent technology transfer to TechInvention Lifecare Limited through a quadripartite license agreement underscores the commitment to bringing this vital innovation from the lab to the global population, bolstering India's self-reliance in public health and contributing significantly to the worldwide effort to eradicate TB by 2030.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The Devdiscourse News Desk		
Date	24 th November, 2025	Language	English
Headline	Revolutionizing TB Immunization: A Novel Vaccine Journey		
Link	https://www.devdiscourse.com/article/health/3708348-revolutionizing-tb-immunization-a-novel-vaccine-journey?amp		



The Indian Institute of Technology (IIT) in Bhubaneswar, along with the Institute of Life Sciences (ILS) and the National Research Development Corporation (NRDC), has formed a significant partnership to advance a new tuberculosis (TB) vaccine. This collaboration looks to bring a groundbreaking alternative to the century-old Bacillus Calmette Guerin (BCG) vaccine.


The initiative took a formal step forward as the three institutions signed a quadripartite license agreement with TechInvention Lifecare Ltd. The focus is on the technology transfer and future commercialization of the 'HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium tuberculosis.'

Developed by ILS and IIT Bhubaneswar, and facilitated by NRDC, the vaccine aims to provide stronger and broader protection than the outdated BCG, addressing a dire global health need. TechInvention Lifecare will be pivotal in transforming this research into a tangible public health solution.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The jagaran		
Date	25 th November, 2025	Language	Hindi
Headline	ILS-IIT Bhubaneswar achieves major breakthrough: Develops new vaccine for TB control, HSP16.3 DC4		
Link	https://www.jagran.com/odisha/bhubaneshwar-ilsit-bhubaneswar-develops-new-tb-vaccine-hsp-163-dc4-40051393.html		



जागरण संवाददाता, भुवनेश्वर। टीबी रोगियों के लिए एक अच्छी खबर आई है। ओडिशा स्थित इंस्टिट्यूट ऑफ लाइफ साइंसेज (आईएलएस) और आईआईटी भुवनेश्वर के वैज्ञानिकों ने टीबी नियंत्रण के लिए एचएसपी 16.3 डीसी4 नामक नया टीका विकसित किया है। इस टीके के फॉर्मूले को मुंबई स्थित टेक इन्वेंशन लाइफकेयर कंपनी को हस्तांतरित किया गया है।

चूहों पर इसका परीक्षण सफल रहा है और अब आगे मानव परीक्षण शुरू होगा। बताया जा रहा है कि यह टीका बहुत जल्द बाजार में उपलब्ध हो सकता है।

जानकारी के मुताबिक, संक्रामक रोग टीबी पिछले चार हजार वर्षों से दुनिया में मौजूद है। विश्वभर में हर साल लाखों लोग इससे संक्रमित होते हैं और पिछले वर्ष ही 12 लाख से अधिक लोगों की जान गई। विश्व स्वास्थ्य संगठन ने 2030 तक दुनिया को टीबी मुक्त करने का लक्ष्य रखा है।

हालांकि, वर्तमान में टीबी से बचाव के लिए सौ साल पहले विकसित बीसीजी टीका लगाया जाता है, जो बच्चों को सीमित सुरक्षा देता है, लेकिन किशोरों और वयस्कों के लिए यह प्रभावी नहीं है। ऐसे समय में टीबी नियंत्रण के लिए नए टीके की आवश्यकता लंबे समय से महसूस की जा रही थी।

ऐसे में अब आईआईटी भुवनेश्वर के प्रोफेसर आशीष विश्वास और आईएलएस भुवनेश्वर के डॉ. सुनील कुमार राघव ने यह नया टीका विकसित किया है, जो बीसीजी टीके की तुलना में अधिक प्रभावशाली माना जा रहा है।



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

राष्ट्रीय अनुसंधान विकास निगम (एनआरडीसी) ने इसके तकनीकी मूल्यांकन के बाद लाइसेंसिंग के लिए कंपनी चयन में मदद की है। टीका फॉर्मूला हस्तांतरण के लिए आईएलएस में एक विशेष कार्यक्रम आयोजित किया गया। आईएलएस, आईआईटी, एनआरडीसी और टेक इन्वेंशन लाइफकेयर के बीच एक एमओयू हस्ताक्षरित हुआ है।

आईएलएस की ओर से बताया गया कि बीसीजी टीके के साथ सब-यूनिट के रूप में इस नए टीके को देने पर इसका प्रभाव और बढ़ जाएगा।

मानव परीक्षण प्रयोगशालाओं में संभव नहीं है, इसलिए इसके लिए टीका निर्माता कंपनियों की मदद आवश्यक है। इस कार्यक्रम में आईएलएस के निदेशक डॉ. देवाशीष दास, आईआईटी भुवनेश्वर के निदेशक प्रोफेसर श्रीपद कर्माकर, डीन (आर एण्ड आइसी) प्रोफेसर दिनकर पासला, एनआरडीसी के वरिष्ठ क्षेत्रीय महाप्रबंधक और प्रमुख (आउटरीच ऑफिस) डॉ. बी.के. साहू, टेक इन्वेंशन लाइफकेयर के निदेशक व सीईओ सैयद एस. अहमद, आईएलएस के वैज्ञानिक डॉ. सुनील राघव और आईआईटी भुवनेश्वर के स्कूल ऑफ बेसिक साइंस के प्रोफेसर डॉ. आशिष विश्वास सहित कई गणमान्य व्यक्ति उपस्थित रहे।

डब्ल्यूएचओ की रिपोर्ट के अनुसार, टीबी दुनिया की सबसे घातक संक्रामक बीमारियों में से एक है, जो अकेले 2024 में 1.23 मिलियन लोगों की जान ले लेती है। संयुक्त राष्ट्र सतत विकास लक्ष्यों (एसडीजी) के तहत 2030 तक टीबी महामारी को समाप्त करना एक प्रमुख वैश्विक स्वास्थ्य प्राथमिकता है।

हालांकि, दुनिया में एक सदी पहले विकसित बैसिलस कैल्मेट गुएरिन (बीसीजी) वैक्सीन पर भरोसा करना जारी रखा है, जो मुख्य रूप से शिशुओं को केवल सीमित सुरक्षा प्रदान करती है और किशोरों और वयस्कों में फुफ्फुसीय टीबी को रोकने में काफी हद तक अप्रभावी है।

इस महत्वपूर्ण अधूरी आवश्यकता को पूरा करने के लिए, भारतीय प्रौद्योगिकी संस्थान (आईआईटी) भुवनेश्वर के प्रोफेसर आशीष विश्वास और इंस्टीट्यूट ऑफ लाइफ साइंसेज (आईएलएस), भुवनेश्वर के डॉ. सुनील कुमार राघव के नेतृत्व में सहयोगात्मक अनुसंधान के माध्यम से अगली पीढ़ी की एचएसपी सब-यूनिट वैक्सीन विकसित की गई है। इस नई वैक्सीन को मौजूदा बीसीजी वैक्सीन की सुरक्षात्मक प्रभावकारिता को बढ़ाते हुए कोशिका-मध्यस्थ प्रतिरक्षा प्रतिक्रियाओं को ट्रिगर करने के लिए डिजाइन किया गया है।



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The OMMCOM News		
Date	25 th November, 2025	Language	English
Headline	IIT Bhubaneswar, ILS And NRDC Sign Pact For Indigenous TB Vaccine Development		
Link	https://ommcomnews.com/odisha-news/iit-bhubaneswar-ils-and-nrdc-sign-pact-for-indigenous-tb-vaccine-development/		



Bhubaneswar: Taking a major stride toward advancing indigenous TB vaccine research, IIT Bhubaneswar, the Institute of Life Sciences (ILS), and the National Research Development Corporation (NRDC) have formalised a Quadripartite License Agreement with TechInvention Lifecare Limited.

The agreement paves the way for technology transfer and potential commercialisation of a promising new vaccine candidate, “HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium tuberculosis.”

The agreement aims to advance the vaccine from laboratory research to product development and eventual commercial deployment.

According to the World Health Organization, TB claimed 1.23 million lives in 2024, making it one of the world’s deadliest infectious diseases.

“However, the world continues to rely on the Bacillus Calmette Guérin (BCG) vaccine, developed over a century ago, which provides only limited protection mainly to infants and is largely ineffective in preventing pulmonary TB in adolescents and adults.

“To address this critical unmet need, a next-generation HSP Subunit Vaccine has been developed through collaborative research led by Prof. Ashis Biswas of IIT, Bhubaneswar and Dr Sunil Kumar Raghav of ILS, Bhubaneswar,” reads a press note issued by the ILS.

This vaccine candidate is designed to trigger strong humoral and cell-mediated immune responses while enhancing the protective efficacy of the existing BCG vaccine.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर
Indian Institute of Technology Bhubaneswar

In view of its significant public health potential, the NRDC proactively identified and evaluated this technology and facilitated the licensing process to ensure its advancement.

“The HSP Subunit Vaccine candidate, jointly developed by the premier institutions ILS and IIT Bhubaneswar, represents a significant advancement in India’s efforts to combat Mycobacterium tuberculosis. This collaboration reflects the robustness of India’s research ecosystem and its commitment to addressing critical public health challenges,” the ILS further added.

TechInvention Lifecare Limited, the licensed industry partner, will play a key role in translating this indigenous vaccine technology into a viable public health solution.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The Odisha Bytes		
Date	25 th November, 2025	Language	English
Headline	IIT-Bhubaneswar & ILS Partner With TechInvention For Roll Out Of TB Vaccine		
Link	https://odishabytes.com/iit-bhubaneswar-ils-partner-with-techinvention-for-roll-out-of-tb-vaccine/amp/		



Bhubaneswar: Indian Institute of Technology (IIT) Bhubaneswar and Institute of Life Sciences (ILS) along with National Research Development Corporation (NRDC) have entered into a quadripartite licence agreement (QLA) with TechInvention Lifecare Limited to transfer and commercialise an innovative next-generation tuberculosis (TB) vaccine targeting *Mycobacterium tuberculosis*.

According to the World Health Organisation, TB claimed 1.23 million lives in 2024, making it one of the world's deadliest infectious diseases.

“However, the world continues to rely on the Bacillus Calmette Guérin (BCG) vaccine, developed over a century ago, which provides only limited protection mainly to infants and is largely ineffective in preventing pulmonary TB in adolescents and adults.

“To address this critical unmet need, a next-generation HSP Subunit Vaccine has been developed through collaborative research led by

Prof. Ashis Biswas of IIT, Bhubaneswar and Dr Sunil Kumar Raghav of ILS, Bhubaneswar,” read a press note issued by the ILS.

This vaccine is designed to induce robust humoral and cellular immune responses while significantly improving the protective effectiveness of the existing BCG vaccine. This is a protein subunit vaccine developed as part of a joint collaboration. “The HSP Subunit Vaccine candidate, jointly developed by the premier institutions ILS and IIT Bhubaneswar, represents a significant advancement in India's efforts to



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

combat *Mycobacterium tuberculosis*. This collaboration reflects the robustness of India's research ecosystem and its commitment to addressing critical public health challenges," the ILS further added.

Under the agreement, TechInvention Lifecare Limited, the industry licensee, will take forward the indigenous technology and translate it into a viable public health solution. It is expected to complete phase-I and II clinical trials within the next four to five years, leveraging its expertise in vaccine development, regulatory compliance, and global health solutions.

"This partnership ensures that the jointly developed vaccine candidate advances efficiently from research to product development, validation and eventual commercialisation. It strengthens India's mission to eliminate tuberculosis and underscores the transformative potential of indigenous, research-driven healthcare innovations for national and global health," said ILS director Debasis Dash.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The South first		
Date	25 th November, 2025	Language	English
Headline	India's new tuberculosis vaccine for adolescents, adults set for market launch		
Link	https://thesouthfirst.com/health/indias-new-tuberculosis-vaccine-for-adolescents-adults-set-for-market-launch/		



India's first tuberculosis vaccine for adolescents and adults – HSP Subunit Vaccine (DDA) – developed by IIT Bhubaneswar and ILS Bhubaneswar, is ready for commercialisation. A quadripartite licence agreement has been signed with TechInvention Lifecare to produce this BCG-boosting vaccine, addressing the critical gap in pulmonary TB protection.

A new tuberculosis (TB) vaccine for adolescents and adults, the HSP Subunit Vaccine in Adjuvant (DDA), is now ready for commercialisation.

Existing vaccines, such as the Bacillus Calmette Guérin (BCG), offer only limited protection, mainly for infants, and are largely ineffective in preventing pulmonary TB in older age groups. The new vaccine aims to fill this critical gap.

The vaccine was developed through collaborative research by IIT Bhubaneswar and the Institute of Life Sciences (ILS), Bhubaneswar, under the Department of Biotechnology.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The New Indian Express		
Date	25 th November, 2025	Language	English
Headline	IIT-BBS & ILS hand new TB vaccine tech to TechInvention		
Link	https://www.newindianexpress.com/states/odisha/2025/Nov/25/iit-bbs-ils-hand-new-tb-vaccine-tech-to-techinvention		



BHUBANESWAR: Indian Institute of Technology (IIT) Bhubaneswar and Institute of Life Sciences (ILS) along with National Research Development Corporation (NRDC) on Monday signed a quadripartite licence agreement (QLA) with TechInvention Lifecare Limited for the technology transfer and commercialisation of a novel TB vaccine against *Mycobacterium tuberculosis*.

Tuberculosis (TB) remains one of the world's deadliest infectious diseases, claiming 1.23 million lives in 2024 alone. The next-generation HSP subunit vaccine has been developed through a collaborative research led by Prof Ashis Biswas of IIT-BBS and Dr Sunil Kumar Raghav of ILS-BBS.

This vaccine candidate has been designed to trigger strong humoral and cell-mediated immune responses while enhancing the protective efficacy of the existing BCG vaccine.

In view of its significant public health potential, NRDC evaluated this technology and facilitated the licencing process to ensure its commercialisation.

Prof Biswas said this is a protein subunit vaccine developed as part of a joint collaboration. "The protein was first developed at the IIT lab and then underwent preclinical trials on mice models at ILS, which tested the efficacy levels. Until now BCG was the only vaccine against TB. The new vaccine if administered after BCG, will act as a booster dose with higher efficiency," he said.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर
Indian Institute of Technology Bhubaneswar

As per the agreement, TechInvention, the licensed industry partner, will help translate this indigenous vaccine technology into a viable public health solution. With strong expertise in vaccine development, regulatory readiness, and global health innovation, TechInvention is expected to complete phase-I and II clinical trials within next four to five years.

“This partnership ensures that the jointly developed vaccine candidate advances efficiently from research to product development, validation and eventual commercialisation. It strengthens India’s mission to eliminate tuberculosis and underscores the transformative potential of indigenous, research-driven healthcare innovations for national and global health,” said ILS director Debasis Dash.



Media/Publication	The Prameya		
Date	25 th November, 2025	Language	Odia
Headline	MoU for exchange of Technology Solutions		

ଆଇଏଲଏସ୍ ପ୍ରତିରୋଧକ ଏବଂସି ୧୭.୩୫ଟି ୪ ଟଙ୍କା

ଚେକୋସ୍ଲୋଭାକି ସ୍ୱତନ୍ତ୍ର ବିନିମୟ ପାଇଁ ଏମ୍ବୋୟ

[illegible][illegible]

ଆସିବା ବେଳେ ପ୍ରାୟ ୫ରୁ ୬ଟି ଲାଗିବ । ଏହି ଟିକା ପୁଷ୍ପାଂଶରେ ୯୦ ଡିଗ୍ରୀ ପର୍ଯ୍ୟନ୍ତ ସ୍ୱଚ୍ଛାବେ ପଡ଼ି ଚାଲିଯିବ । ପ୍ରାୟ ୩ ମିନିଟ୍ ୨୫ରୁ ୩୫ ମିନିଟ୍ ପର୍ଯ୍ୟନ୍ତ ସମ୍ପୂର୍ଣ୍ଣ ପୁରଣା ଦେଖାଯିବ । ଏହା ଦେଖିବା କରି ପୁରୁଷଙ୍କ ଶେରୁରେ ସ୍ୱଚ୍ଛାବେ ହେବ । ଦେଖିବା ଲାଗିବ ଏହା ଟିକିମୁକ୍ତ କରିବା ଦିଗରେ ପୁରଣା କରବ କରି କାର୍ଯ୍ୟ କରିବ । ଆଉ ଏହି ସବୁ ପୁରୁଷ ମିଳିଥିବା ପୁରୁଷ ଥରପ୍ରଥମ, ବର୍ଷପ୍ରଥମ ଯେଉଁ ଲବିକର କାଳମେ-ରୁ ଏପରି (ବିପଦି) ଟିକା ଦିଆଯାଉଛି । ତାହା ଉପକ୍ରମେ ଏହି ଟିକା ଦିଆ ଏବଂ ଏହା

୧୬. ଗୀତପିଠ ବହୁତ ପୁରାତନ । ଏହି ଚିନ୍ତା
କୋଷିକାର ଶି-ସେଇ ମେଗୋରା ଓ ଶି-ସେଇ
ମେଗୋରାହିଁ ନିରନ୍ତର ସଂସ୍କୃତ ରଞ୍ଜିତ୍ୟ-ଏ ।
ଯଥାପଦରେ ନିରନ୍ତର ବାବାଘୁ ଗାନ୍ଧିର ଦିଗରେ
ସଂଗ୍ରାମ କରିଥାଏ । ଏହା ପୁରପୁଞ୍ଜିକ ଶ୍ରେଷ୍ଠରେ
ଭଲ କର୍ମ୍ୟ କରିବ । ଯଥା କୋବେଶୁ ଗୁପ୍ତା ଯନ୍ତ୍ରା
ପୁତିରେଖର ଶଗଡ଼ା ଓ ପୁତିରେଖ ଦେବପାଣିର ।
ଏହା ବାବାଘୁ ନିରୋଧରେ ଭାବେ ସମୟ ଧରି ରୋଧ
ପୁତିରେଖର ଶକ୍ତି ବୁଝି କରିବ । ଏହା କୋଷାଂଶ
ଏବଂ ହୁଏମୋରାହିଁ ପୁତିରେଖ ଭରସା ବୁଝି କରି
ସରସୋପାଧି ବାବାଘୁ ନିରୋଧରେ ଭାବିବ ।



Media/Publication	The Pioneer		
Date	25 th November, 2025	Language	English
Headline	IIT, ILS provide novel TB vaccine tech		

IIT, ILS provide novel TB vaccine tech



RAJEEV RATHAN ■ Bhubaneswar

The Indian Institute of Technology (IIT) Bhubaneswar and the Institute of Life Sciences (ILS), Bhubaneswar, along with the National Research Development Corporation (NRDC), have signed a Quadripartite Licence Agreement (QLA) with the TechInvention Lifecare Limited for technology transfer and future commercialisation of a novel TB vaccine candidate titled "HSP Subunit Vaccine in Adjuvant (DDA) Against Myco-

bacterium tuberculosis".

Tuberculosis (TB) remains one of the world's deadliest infectious diseases, claiming 1.23million lives in 2024 alone, as reported by the WHO. Ending the TB epidemic by 2030 is a key global health priority under the United Nations Sustainable Development Goals (SDGs). However, the world continues to rely on the Bacillus Calmette Guérin (BCG) vaccine, developed over a century ago, which provides only limited protection mainly to infants and is largely ineffective in preventing pulmonary TB in adolescents and adults.

To address this critical unmet need, a next-generation HSP Subunit Vaccine has been developed through collaborative research led by Prof Ashis Biswas of IIT Bhubaneswar and Dr Sunil Kumar Raghav of ILS Bhubaneswar. This vaccine candidate is designed to trigger strong humoral and cell-mediated immune responses while enhancing the protective efficacy of the existing BCG vaccine.

TechInvention Lifecare Limited will play a key role in translating this indigenous vaccine technology into a viable public health solution.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर

Indian Institute of Technology Bhubaneswar

Media/Publication	The Statesman		
Date	25 th November, 2025	Language	English
Headline	IIT-Bhubaneswar & ILS transfer Novel TB Vaccine Technology to TechInvention		

IIT-Bhubaneswar & ILS transfer Novel TB Vaccine Technology to TechInvention

STATESMAN NEWS SERVICE
Bhubaneswar, 24th November

Indian Institute of Technology (IIT) Bhubaneswar and the Institute of Life Sciences (ILS) Bhubaneswar, along with the National Research Development Corporation (NRDC), have signed a Quality Partnership Agreement (QPA) with TechInvention. License transfer and future commercialisation of novel TB vaccine candidate titled "BSP Subunit Vaccine in Adjuvant (BGSV) Against Mycobacterium tuberculosis".

Tuberculosis (TB) remains one of the world's deadliest infectious diseases, claiming 1.25 million lives in 2024 alone, as reported by the WHO. Despite the TB epidemic, by 2030 is also global health priority under the United Nations Sustainable Development Goals (SDGs). However, the world continues to rely on the BCG vaccine, developed over a century ago, which provides only limited protection mainly to infants and is largely ineffective in



preventing pulmonary TB in adolescents and adults.

To address this critical unmet clinical need, the BSP Subunit Vaccine has been developed through collaborative research led by Prof. Ashis Ghose of Indian Institute of Technology (IIT) Bhubaneswar and Dr. Sanil Kumar Raychaudhary of Institute of Life Sciences (ILS), Bhubaneswar.

The vaccine candidate is designed to trigger strong humoral and cell-mediated immune response while enhancing the protective efficacy of the existing BCG vaccine, thus offering significant public health potential. National Research Development Corporation (NRDC) has provided financial and technical support and facilitated the licensing

process to ensure its advancement.

The technology exchange was held at ILS Bhubaneswar in the presence of several senior dignitaries including Dr. Debasis Dash, Director, ILS; Prof. Manoj Kumar Ghosh, Director, IIT Bhubaneswar; Prof. Dinkar Patel, Dean (Sponsored Research) & Industrial Connectivity, IIT Bhubaneswar; Dr. R.K. Jais, Senior Regional Manager & Head - Outreach Office, NRDC South; and Dr. Sanil Kumar Raychaudhary, Scientist F, ILS Bhubaneswar; Dr. Ashis Ghose, Professor, School of Basic Science, IIT Bhubaneswar, along with other distinguished guests.

The BSP Subunit Vaccine candidate jointly developed

by the partner institutions ILS and IIT Bhubaneswar represents a significant advancement in efforts to combat Mycobacterium tuberculosis. This collaboration reflects the robustness of Indian research ecosystem and its commitment to addressing critical public health challenges.

TechInvention, a leading life sciences incubator and partner, will play a key role in translating the indigenous vaccine technology into a viable public health solution. With strong expertise in vaccine development, regulatory readiness, and global market innovation, TechInvention brings deep technical strength and established manufacturing capabilities.

This partnership ensures that the jointly developed vaccine candidate moves efficiently from research to pre-clinical development, validation, and eventual commercialisation.

It strengthens India's vaccine manufacturing ecosystem, enhances the readiness for arrival of indigenous research-driven health innovations from national and global health.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The Political and Business Daily		
Date	25 th November, 2025	Language	English
Headline	IIT Bhubaneswar, ILS transfer novel TB vaccine technology to TechInvention		

IIT Bhubaneswar, ILS transfer novel TB vaccine technology to TechInvention

PBD BUREAU/PTI

BHUBANESWAR, NOV 24

THE Bhubaneswar-based Indian Institute of Technology (IIT), the Institute of Life Sciences (ILS) along with the National Research Development Corporation (NRDC), have joined hands for the technology transfer and future commercialisation of a novel TB vaccine, officials said.

The three organisations signed a quadripartite license agreement (QLA) with TechInvention Lifecare Ltd here on Monday for the technology transfer and future commercialisation of 'HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium tuberculosis'.

The HSP Subunit Vaccine candidate was jointly developed by the premier institu-



tions ILS and IIT Bhubaneswar, while NRDC identified and evaluated the technology and facilitated the licensing process to ensure its advancement, an official said.

TechInvention Lifecare Limited, the licensed industry partner, will play a key role in translating this indigenous vaccine technology into a viable public health solution, he said.

Tuberculosis (TB) remains one of the world's deadliest infectious diseases, claiming 1.23 million lives in 2024 alone, as per the WHO report.

Ending the TB epidemic by 2030 is a key global health priority under the United Nations Sustainable Development Goals (SDGs), the IIT said in a statement on Monday.

However, the world continues to rely on the Bacillus Calmette Guerin (BCG) vaccine, developed over a century ago, which provides only limited protection mainly to infants and is largely ineffective in preventing pulmonary TB in adolescents and adults, it said.

To address this critical unmet need, a next-generation

HSP Subunit Vaccine has been developed through collaborative research led by Ashis Biswas of IIT Bhubaneswar and Sunil Kumar Raghav of ILS, Bhubaneswar.

The IIT claimed that the vaccine candidate is designed to trigger strong humoral and cell-mediated immune responses while enhancing the protective efficacy of the existing BCG vaccine.

This partnership ensures that the jointly developed vaccine candidate advances efficiently from research to product development, validation, and eventual commercialisation, as per the statement.

It strengthens India's mission to eliminate tuberculosis and underscores the transformative potential of indigenous, research-driven healthcare innovations for national and global health, the institute said.



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The Orissa Post		
Date	25 th November, 2025	Language	English
Headline	City institutes transfer novel TB vaccine tech.		

City institutes transfer novel TB vaccine tech

IPON & AGENCIES

Bhubaneswar, Nov 24: The Bhubaneswar-based Indian Institute of Technology (IIT), the Institute of Life Sciences (ILS) along with the National Research Development Corporation (NRDC), have joined hands for the technology transfer and future commercialisation of a novel TB vaccine, officials said.

The three organisations signed a quadripartite license agreement (QLA) with TechInvention Lifecare Ltd here Monday for the technology transfer and future commercialisation of 'HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium tuberculosis'.

The HSP Subunit Vaccine candidate was jointly developed by the premier institutions ILS and IIT Bhubaneswar, while NRDC identified and evaluated the technology and facilitated the licensing process to ensure its advancement, an official said.

TechInvention Lifecare Limited, the licensed industry partner, will play a key role in translating this indigenous vaccine technology into a viable public health solution, he said.

Tuberculosis (TB) remains one of the world's deadliest infectious diseases, claiming 1.23 million lives in 2024 alone, as per the WHO report.

Ending the TB epidemic by 2030 is a key global health priority under the United Nations Sustainable Development Goals (SDGs), the IIT said in a statement on Monday.

However, the world continues to rely on the Bacillus Calmette Guérin (BCG) vaccine, developed over a century ago, which provides only limited protection mainly to infants and is largely ineffective in preventing pulmonary TB in adolescents and adults, it said.

To address this critical unmet need, a next-generation HSP Subunit Vaccine has been developed through collaborative research led by Ashis Biswas of IIT Bhubaneswar and Sunil Kumar Raghav of ILS, Bhubaneswar.

The IIT claimed that the vaccine candidate is designed to trigger strong humoral and cell-mediated immune responses while enhancing the protective efficacy of the existing BCG vaccine.

This partnership ensures that the jointly developed vaccine candidate advances efficiently from research to product development, validation, and eventual commercialisation, as per the statement.

It strengthens India's mission to eliminate tuberculosis and underscores the transformative potential of indigenous, research-driven healthcare innovations for national and global health, the institute said.



Media/Publication	The Sambad		
Date	25 th November, 2025	Language	Odia
Headline	New vaccines for tuberculosis to be launched		

ଆଇଏଲ୍‌ଏସ୍, ଆଇଆରଟି
ଭୁବନେଶ୍ୱରକୁ ସଫଳତା

[illegible]


ମାତ୍ରାମାନ ଯୋଗ ଯଥା ଦିଶୁଥିବା ବିକାଶ
କାରକର ବର୍ଣ୍ଣ ପ୍ରତି ଉପସ୍ଥିତି ଦିଶୁଥିବା ଲକ୍ଷଣ
କେବଳ ପ୍ରତିବର୍ଣ୍ଣ ଥିବା ମାତ୍ରାମାନ ଯୋଗାଯୋଗ

ବେଳେ ବାବର୍ଷି ୧୨ଲକ୍ଷରୁ ଅଧିକ ଲୋକଙ୍କ
ଜୀବନ ପାରିଛି। ଦିଶୁ ଟୁଣ୍ଡା ଖଜରନ(ହୁ)
ପଥରୁ ୨୦୩୦ ଟୁଣ୍ଡା ପଡ଼ାକାଠି ଭେଦା ପାଏ



କଟକ ଗସ୍ତି: ପ୍ରସ୍ତାବକୁ ଗ୍ରହଣ ପାଇଁ ଏବେ ବି
କଟକ ବର୍ଷ ପୂର୍ବରୁ ଉଦ୍ଧାରଣ ହୋଇଥିବା ବିବିଧି
ବିଷୟ ବିଷୟବସ୍ତୁ ଶିଶୁଙ୍କୁ ଏହା ସମ୍ପର୍କିତ ଗ୍ରହଣ

ଦେଉଆରୀ ଦେଶର ବିଶେଷତା ଦିଆଁ ଦେଉଆରୀ
 ପାଇଁ ପ୍ରସ୍ତୁତ କରାଯାଇଛି । ଏହା ଗୋଟିଏ
 ସାମାଜିକ ଦିବସ ପାଇଁ ପ୍ରଥମ ବିଭାଗ ଆବେଦନ
 କରିପାରେ । ଆଉଟରାଣ୍ଟି କୁଳଦେବତାଙ୍କ ପ୍ରାଣେ
 ଆଶିଷ ଦିଆଯାଏ ଏବଂ ଏହାକୁ କୁଳଦେବତାଙ୍କ
 ଚାନ୍ଦିନୀଙ୍କ ଦ୍ଵାରା ଗ୍ରହଣ କରି ପ୍ରଥମ ବିଭା
 ଦେବତାଙ୍କ କରାଯାଏ । ଏହି ବିଭା ଦେବତାଙ୍କ ବିଭା
 କୁଳଦେବତାଙ୍କ ଦିବସ ପ୍ରସ୍ତୁତ କରାଯାଏ । ଏହା
 ଦେବତାଙ୍କ ବିଭା (ଏହାଦେବତାଙ୍କ) ପ୍ରସ୍ତୁତ କରି
 ଦେବତାଙ୍କ ଆବେଦନକାରୀଙ୍କ ଦ୍ଵାରା କରାଯାଏ ।
 ପ୍ରଥମ ବିଭା ପ୍ରସ୍ତୁତ କରାଯାଏ । ଏହା
 ଦେବତାଙ୍କ ପ୍ରଥମ ବିଭା ଆବେଦନକାରୀଙ୍କ ଦ୍ଵାରା
 କରାଯାଏ । ଏହା ଦେବତାଙ୍କ ଦେବତାଙ୍କ ଦେବତାଙ୍କ
 ଦେବତାଙ୍କ ଦେବତାଙ୍କ ଦେବତାଙ୍କ ଦେବତାଙ୍କ
 ଦେବତାଙ୍କ ଦେବତାଙ୍କ ଦେବତାଙ୍କ ଦେବତାଙ୍କ





भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The Sakala		
Date	25 th November, 2025	Language	odia
Headline	ILS's tuberculosis vaccine research successful		

ଆଇଏଲ୍‌ଏସ୍‌ର ଯକ୍ଷ୍ମା ଟିକା ଗବେଷଣା ସଫଳ



■ ଭୁବନେଶ୍ୱର, ୨୪।୧୧ (ସମ୍ବିଧ): ଯକ୍ଷ୍ମା ନ୍ୟାସନାଲ ଇନିସିଟିଭ ଡେଭଲପମେଣ୍ଟ କର୍ପୋରେସନ୍
ବିଭାଗରେ ଦିଗରେ ଏକ ଅନୁତପୂର୍ବ ପକ୍ଷରୁ ଟେକ୍-ଇନଭେନସନ୍ ଜାରିତ କେୟାର
ସଫଳତା ମିଳିଛି। ଭୁବନେଶ୍ୱର ଆଇଆଇଟି ଏବଂ ଜୀବ ବିଜ୍ଞାନ ପ୍ରତିଷ୍ଠାନ (ଆଇଏଲ୍‌ଏସ୍),
ଭୁବନେଶ୍ୱର ମିଳିତ ଭାବେ ବିଶ୍ୱ ବଜାରରେ ଟିକା ପହଞ୍ଚାଇବା ପାଇଁ ଏମ୍‌ଓୟୁ ସ୍ୱାକ୍ଷରିତ
ଏକ ପ୍ରକାଶନା ଯକ୍ଷ୍ମା ଟିକାର ଉତ୍ପାଦନ କରିଛନ୍ତି। ଏହି ଟିକାକୁ ବିଶ୍ୱ ପ୍ରଫେସର୍ ଆଶିଷ ବିଶ୍ୱାସ, ଆଇଏଲ୍‌ଏସ୍‌ର ଡ.
ହଜାରରେ ପହଞ୍ଚାଇବା ଏବଂ ଅଧିକ ଗବେଷଣା ସୁନାମ କୁମାର ରାଘବଙ୍କ ନେତୃତ୍ୱରେ ଗବେଷକଙ୍କ
ପାଇଁ ସାମାଜିକ ଆଇଆଇଟି, ଆଇଏଲ୍‌ଏସ୍‌ ଏବଂ ଏକ ଏହି ସଫଳତା ପାଇଛି।

ବିଶ୍ୱ ବଜାରରେ ଟିକା
ପହଞ୍ଚାଇବା ପାଇଁ
ଏମ୍‌ଓୟୁ ସ୍ୱାକ୍ଷରିତ



Media/Publication	The Sarkar		
Date	25 th November, 2025	Language	Odia
Headline	Clinical trials of tuberculosis vaccine to begin soon.		

■ ଆଇଆଇଟି ଭୁବନେଶ୍ୱରର ସହଯୋଗରେ ଟିକା ପ୍ରସ୍ତୁତ

ଖୁବ୍‌ଶୀଘ୍ର ଯକ୍ଷ୍ମା ଟିକାର କ୍ଲିନିକାଲ ଟ୍ରାଏଲ୍

ଖୋର୍ଦ୍ଧା, ୨୪।୧୧(ସ.ପ୍ର): ଭାରତୀୟ ପ୍ରଯୁକ୍ତି ବିଦ୍ୟା ପ୍ରତିଷ୍ଠାନ (ଆଇଆଇଟି) ଭୁବନେଶ୍ୱର, ଜଟଣୀ ଏବଂ ଜନଶ୍ୱିରୂପ ଅଫ ଲାଇଫ ସାଇନ୍ସେସ (ଆଇଏଲଏସ), ଭୁବନେଶ୍ୱର, ଜାତୀୟ ଗବେଷଣା ବିକାଶ ନିଗମ (ଏନଆରଡିଏ) ସହିତ, “ଏନଏସପି ସବଲୁନିଟ୍ ଭାକସିନ ଜନ୍ ଆଡକୁଭାଣ୍ଟ (ଡିଡିଏ) ଏଗନେଷ୍ଟ ମାଇକ୍ରୋ ବ୍ୟାକ୍ଟେରିୟା ଟ୍ୟୁବରକୁଲୋସିସ୍” ଶୀର୍ଷକ ଏକ ନୂତନ ଯକ୍ଷ୍ମା ଟିକା କ୍ୟାଣ୍ଡିଡେଟର ପ୍ରଯୁକ୍ତିବିଦ୍ୟା ହସ୍ତାନ୍ତର ଏବଂ ଭବିଷ୍ୟତର ବ୍ୟବସାୟକରଣ ପାଇଁ ଟେକ୍ନୋଲୋଜିକାଲ ଲାଇଫସାଇନ୍ସେସ ଲିମିଟେଡ୍ ସହିତ ଏକ ଚତୁର୍ଥାଂଶିକ ଲାଇସେନ୍ସ ଚୁକ୍ତିନାମା ସ୍ୱାକ୍ଷର କରିଛନ୍ତି । ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନ ଦ୍ୱାରା ରିପୋର୍ଟ କରାଯାଇଥିବା ରିପୋର୍ଟ ଅନୁଯାୟୀ, ଯକ୍ଷ୍ମା (ଟିବି) ବିଶ୍ୱର ସବୁଠାରୁ ମାରାତ୍ମକ ସଂକ୍ରମକ ରୋଗ ମଧ୍ୟରୁ ଗୋଟିଏ ଯାହା କେବଳ ୨୦୨୪ରେ ୧.୨୩ ନିୟୁତ ଲୋକଙ୍କ ଜୀବନ ନେଇଛି । ୨୦୩୦ ସୁଦ୍ଧା ଯକ୍ଷ୍ମା ମହାମାରୀ ସମାପ୍ତ କରିବା ହେଉଛି ଜାତିସଂଘର ସ୍ୱାସ୍ଥ୍ୟ ବିକାଶ ଲକ୍ଷ୍ୟ (ଏସଡିଜି) ଅଧୀନରେ ଏକ ପ୍ରମୁଖ ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ପ୍ରାଥମିକତା । ତଥାପି, ବିଶ୍ୱ ଏକ ଶତାବ୍ଦୀ ପୂର୍ବରୁ ବିକଶିତ ବାସିଲସ୍ କାଲମେଟ୍ ଗୁଏରିନ୍ (ବିସିଜି) ଟିକା ଉପରେ ନିର୍ଭର କରିଆସୁଛି, ଯାହା ମୁଖ୍ୟତଃ ଶିଶୁମାନଙ୍କୁ କେବଳ ସାମିତ ସୁରକ୍ଷା ପ୍ରଦାନ କରେ ଏବଂ କିଶୋର ଏବଂ ବୟସ୍କମାନଙ୍କ ମଧ୍ୟରେ ପୂର୍ବସୂଚ୍ୟ ଯକ୍ଷ୍ମା ରୋକିବାରେ ମୁଖ୍ୟତଃ



ପ୍ରଭାବହୀନ । ଏହି ଗୁରୁତ୍ୱପୂର୍ଣ୍ଣ ଅପରୀକ୍ଷିତ ଆବଶ୍ୟକତାକୁ ପୂରଣ କରିବା ପାଇଁ, ଭାରତୀୟ ପ୍ରଯୁକ୍ତି ପ୍ରତିଷ୍ଠାନ (ଆଇଆଇଟି) ଭୁବନେଶ୍ୱର ଜଟଣୀର ପ୍ରଫେସର ଆଶିଷ ବିଶ୍ୱାସ ଏବଂ ଭୁବନେଶ୍ୱରର ଜନଶ୍ୱିରୂପ ଅଫ ଲାଇଫ ସାଇନ୍ସେସ (ଆଇଏଲଏସ)ର ଡ. ସୁନୀଲ କୁମାର ରାୟଙ୍କ ନେତୃତ୍ୱରେ ଗଠିତ ଗବେଷଣା ମାଧ୍ୟମରେ ଏକ ପରବର୍ତ୍ତୀ ପିଢ଼ିର ଏବଂଏସପି ସବଲୁନିଟ୍ ଟିକା ବିକଶିତ କରାଯାଇଛି । ଏହି ଟିକା କ୍ୟାଣ୍ଡିଡେଟ ବିସିଜି ଟିକାର ସୁରକ୍ଷାମୂଳକ ପ୍ରଭାବକୁ ବୁଝି କରିବା ସହିତ ଦୃଢ଼ ହିସାବମୋରାଲ୍ ଏବଂ କୋଷ-ମଧ୍ୟସ୍ଥଳୀ ପ୍ରତିରକ୍ଷା ପ୍ରତିକ୍ରିୟାକୁ ଡିଗ୍ରୀ କରିବା ପାଇଁ ଡିଜାଇନ୍ କରାଯାଇଛି । ଏହାର ଗୁରୁତ୍ୱପୂର୍ଣ୍ଣ ସାର୍ବଜନୀନ ସ୍ୱାସ୍ଥ୍ୟ ସମ୍ପାଦନାକୁ ଦୃଷ୍ଟିରେ ରଖି, ଜାତୀୟ ଗବେଷଣା ବିକାଶ ନିଗମ (ଏନଆରଡିଏ) ଏହି ପ୍ରଯୁକ୍ତିବିଦ୍ୟାକୁ ସକ୍ରିୟ ଭାବରେ ଚିହ୍ନଟ ଏବଂ ମୂଲ୍ୟାଙ୍କନ କରିଥିଲା ଏବଂ ଏହାର ଉନ୍ନତିକୁ ସୁନିଶ୍ଚିତ କରିବା ପାଇଁ

ଲାଇସେନ୍ସ ପ୍ରକ୍ରିୟାକୁ ସହଜ କରିଥିଲା । ଏହି ପ୍ରଯୁକ୍ତିବିଦ୍ୟା ବିନିମୟ ଆଇଏଲଏସ୍ ଭୁବନେଶ୍ୱର ପରିସରରେ ଅନେକ ବରିଷ୍ଠ ମାନ୍ୟଗଣ୍ୟ ବ୍ୟକ୍ତିଙ୍କ ଉପସ୍ଥିତିରେ ଅନୁଷ୍ଠିତ ହୋଇଥିଲା । ଯେଉଁଥିରେ ଆଇଆଇଟି ଭୁବନେଶ୍ୱର ନିର୍ଦ୍ଦେଶକ ପ୍ରଫେସର ଶ୍ରୀପଦ କରମଲକର; ଆଇଏଲଏସର ନିର୍ଦ୍ଦେଶକ ଡ. ଦେବାଶିଷ ଦାଶ; ଆଇଆଇଟି ଭୁବନେଶ୍ୱରର ଡିନ୍ (ପ୍ରାୟୋଜିତ ଗବେଷଣା ଏବଂ ଶିଳ୍ପ ପରାମର୍ଶଦାତା) ପ୍ରଫେସର ଦିନକର ପାସଲା, ଏନଆରଡିଏର ବରିଷ୍ଠ ଆଞ୍ଚଳିକ ପରିଚାଳକ ଏବଂ ଆଉଟରିଚ୍ କାର୍ଯ୍ୟାଳୟ ମୁଖ୍ୟ ଡ. ବି.କେ. ସାହୁ; ଟେକ୍ନୋଲୋଜିକାଲ ଲାଇଫସାଇନ୍ସେସ ଲିମିଟେଡ୍‌ର ନିର୍ଦ୍ଦେଶକ ଏବଂ ସିଇଓ ସୟଦ ଏସ୍. ଅହମ୍ମଦ, ଆଇଏଲଏସ୍ ଭୁବନେଶ୍ୱରର ବୈଜ୍ଞାନିକ (ଏସ) ଡ. ସୁନୀଲ କୁମାର ରାୟ, ଆଇଆଇଟି ଭୁବନେଶ୍ୱରର ସ୍କୁଲ ଅଫ୍ ବେସିକ୍ ସାଇନ୍ସେସ ପ୍ରଫେସର ଡ. ଆଶିଷ ବିଶ୍ୱାସ ଏବଂ ଅନ୍ୟାନ୍ୟ ସମ୍ମାନିତ ଅତିଥିମାନେ ଉପସ୍ଥିତ ଥିଲେ ।



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The Bizzbuzz news		
Date	26 th November, 2025	Language	Odia
Headline	IIT Bhubaneswar signs pact for novel TB vax tech		
Link	https://www.bizzbuzz.news/industry/pharma/iit-bhubaneswar-signs-pact-for-novel-tb-vax-tech-1378776		



Bhubaneswar: Taking a major stride toward advancing indigenous TB vaccine research, IIT Bhubaneswar, the Institute of Life Sciences (ILS), and the National Research Development Corporation (NRDC) have formalised a Quadripartite License Agreement with TechInvention Lifecare Limited.

<https://www.bizzbuzz.news/industry/pharma/iit-bhubaneswar-signs-pact-for-novel-tb-vax-tech-1378776>



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर Indian Institute of Technology Bhubaneswar

Media/Publication	The PSU Watch		
Date	25 th November, 2025	Language	Odia
Headline	IIT Bhubaneswar, ILS transfer novel TB vaccine technology to TechInvention Lifecare; NRDC facilitates licensing		
Link	https://psuwatch.com/newsupdates/iit-bhubaneswar-ils-transfer-novel-tb-vaccine-technology-to-techinvention-lifecare-nrdc-facilitates-licensing		



The agreement covers the technology transfer and commercialization of a next-generation vaccine candidate, “HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium tuberculosis,” developed to address the limitations of the century-old Bacillus Calmette Guérin (BCG) vaccine currently in use.

According to WHO estimates, tuberculosis claimed 1.23 million lives in 2024, remaining one of the world’s deadliest infectious diseases. The new vaccine candidate aims to generate strong humoral and cell-mediated immune responses and is designed to improve the protective efficacy of the existing BCG vaccine, especially among adolescents and adults—groups where BCG has shown limited effectiveness.

The technology has been jointly developed by Prof. Ashis Biswas of IIT Bhubaneswar and Dr. Sunil Kumar Raghav of ILS Bhubaneswar. NRDC proactively identified and evaluated the innovation and facilitated the licensing process to accelerate its advancement towards commercialization.

The technology exchange ceremony was held at ILS Bhubaneswar in the presence of senior officials, including ILS Director Dr. Debasis Dash; IIT Bhubaneswar Director Prof. Shreepad Karmalkar; IIT Bhubaneswar Dean (Sponsored Research & Industrial Consultancy) Prof. Dinakar Pasla; NRDC Senior Regional Manager Dr. B. K. Sahu; TechInvention Lifecare Director & CEO Syed S. Ahmed; Dr. Raghav; and Prof. Biswas, among others.

The HSP Subunit Vaccine represents a significant milestone in India’s scientific efforts to develop advanced interventions against Mycobacterium tuberculosis. The collaboration underscores the strength of



भारतीय प्रौद्योगिकी संस्थान भुवनेश्वर
Indian Institute of Technology Bhubaneswar

India's research ecosystem and its commitment to addressing major public health challenges through indigenous innovation.

TechInvention Lifecare Limited, the licensed industry partner, will lead the transition of the technology from the research stage to product development, validation and eventual market readiness. With experience in vaccine development, manufacturing and regulatory processes, the company is expected to play a pivotal role in ensuring the vaccine candidate moves efficiently through the development pipeline.